Objective To investigate the function and regulatory mechanisms of VCAN gene and protein in metastatic prostate cancer.Methods The data of whole genomic expression profiles got from the prostate cancer metastasis were obtained from gene expression omnibus (GEO) database,a set of bioinformatics tools,such as BRB-Array Tools,protparam,SMART,SignalP 4.0,TMHMM,NetPhos2.0,PredictProtein,SWISS-MODEL,GO,KEGG and STRING softwares were used to accomplish data-mining and bioinformatics analysis.Results There were 73 co-expressed differentially genes in prostate cancer metastasis,21 up-regulated and 52 down-regulated.Bioinformatics analysis indicated that VCAN gene encoded 3396 amino acids,VCAN was also contained one Immunoglobulin domain,two hyaluronan-binding domain,one epidermal growth factor-like domain,one calcium-binding EGF-like domain,one C-type lectin domain and one domain abundant in complement control proteins,and a furthermore analysis suggested that VCAN played essential roles in such important biological function including cell adhesion,hyaluronic acid binding,calcium-binding,glycosaminoglycan binding,extracellular matrix and cell adhesion molecules.Conclusions Bioinformatics analysis had a high efficiency in analyzing microarray data and revealing internal biology information.VCAN may play an important role in the prostate cancer metastasis,Thus,VCAN might be a novel biomarker for the diagnosis of prostate cancer metastasis or a new target for its treatment.

【Objective】 To analyze the expression of lncRNA SNHG25 in prostate cancer and its significance, so as to explore the biomarkers and potential therapeutic targets for the diagnosis and prognosis of this disease. 【Methods】 Based on the TCGA database, differential, survival, and clinical correlation analyses of SNHG25 were performed.SNHG25 expression in prostate cancer was analyzed in the UALCAN database to determine its relationship with the clinical and pathological characteristics.The lncRNA-miRNA-mRNA correlation analysis was performed.The relevant ceRNA regulatory network was constructed.Prostate cancer samples were divided into high and low SNHG25 expression groups, and differential SNHG25 related genes were filtered and then enriched. 【Results】 SNHG25 expression was significantly upregulated in prostate cancer specimens compared to normal prostate specimens (P<0.001), and the progression-free survival of the low SNHG25 expression group was significantly longer than that of the high SNHG25 expression group (P<0.001).There were no significant differences in age, T-stage and N-stage between the two groups, and there was no significant correlation between the expression of SNHG25 and Gleason score (P>0.05).Regulatory networks of SNHG25/miR-330-3p/DLX1 and RPL22L1 were constructed. 【Conclusion】 SNHG25 is highly expressed in prostate cancer tissues and correlated with poor prognosis.SNHG25 expression does not significantly correlate with age, T-stage, N-stage, and Gleason score.SNHG25/miR-330-3p/DLX1 and RPL22L1 regulatory networks may play an important role in the development of prostate cancer.SNHG25 may become a biomarker and potential therapeutic target for prostate cancer.